Home
Storia in 1 fonti
Johnson & Johnson advances IBD therapy, despite trial miss
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
Raccontata da
statnews.com
- ·
Johnson & Johnson advances IBD therapy, despite trial miss
A closely watched therapy developed by Johnson & Johnson failed to show a statistically meaningful improvement for IBD patients.
- ·
Are analysts too quick to gloss over Lilly's liver case?
Cytokinetics' Myqorzo's trial results, Johnson & Johnson's IBD therapy, and more biotech news from The Readout